Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas

The combination of bortezomib, cladribine, and rituximab is novel and effective in mantle-cell and indolent non-Hodgkin lymphomas.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Soham D. Puvvada, Jos é Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan, Daniel O. Persky Tags: Original Study Source Type: research